Executive Summary

On May 27, 2026, the Swiss Federal Council approved an increase in the federal contribution to Swissmedic of CHF 2.7 million for 2027. The financing commitment is contingent on the full implementation of cost-saving measures decided by the Board of Directors in November 2025. Simultaneously, the Federal Council approved the revision of the fee regulation, which introduces a new registration fee for medical devices. This will become mandatory as of July 1, 2026.

Persons

  • Federal Department of Home Affairs (supervisory authority)

Topics

  • Swissmedic financing
  • Medicinal product regulation
  • Medical device registration
  • Federal budget 2027

Clarus Lead

The financing crisis at Swissmedic forces the Federal Council to adopt a conditional strategy: the contribution increase becomes a lever for cost savings. Swissmedic must save a total of CHF 15 million – a structural restructuring program that puts the regulatory authority under pressure. The new registration fee for medical devices also shifts administrative costs to industry and signals a paradigm shift in financing logic following Switzerland's exclusion from European medical device oversight in 2021.

Detailed Summary

Swissmedic is financed from three sources: supervisory fees, charges, and federal contributions. The federal government currently covers approximately 17 percent of costs (CHF 19.3 million), while 83 percent comes from fees and charges. The increase to CHF 22 million is legally justified: tasks in legislation, law enforcement, and medical device oversight must be fully financed by the federal government.

The cost-saving requirements are concretely quantified: CHF 9 million in savings on personnel costs (9 percent of personnel cost budgets) and CHF 6 million in material costs. These measures were decided by the Board of Directors in November 2025 and are a condition for the contribution increase. The Department of Home Affairs will be regularly informed about implementation.

The new registration fee for medical devices targets the swissdamed database, which has served as a national transparency solution since Switzerland's EU exclusion in 2021. It collects product information and company details and creates clarity in the Swiss market. The hourly rate for fees based on effort is being adjusted for inflation for the first time since 2002 – an administrative adjustment that was long overdue.

Key Points

  • Federal Council increases Swissmedic contribution by CHF 2.7 million to CHF 22 million for 2027
  • Financing commitment is tied to CHF 15 million cost-saving package
  • New registration fee for medical devices as of July 1, 2026 (with transition period until December 31, 2026)
  • Fee rates adjusted for inflation for the first time in 24 years

Critical Questions

  1. Evidence/Data Quality: Is the quantification of cost-saving measures (CHF 15 million) based on detailed cost analysis, or is it a politically determined target figure? What criteria define "full implementation"?

  2. Conflicts of Interest: To what extent could Swissmedic's dependence on fees and supervisory charges (83 percent of financing) jeopardize its regulatory independence from the pharmaceutical industry, especially in light of cost-saving measures?

  3. Causality: Are Swissmedic's cost increases primarily attributable to inefficiency, or do they reflect increased requirements in medical device oversight following the 2021 EU exclusion?

  4. Feasibility: How will it be ensured that CHF 9 million in personnel cost reduction (9 percent) does not lead to quality loss in drug and medical device approval?

  5. Side Effects: Could the new registration fee for medical devices disproportionately burden small and medium-sized enterprises and thereby promote market concentration?

  6. Transparency: Will cost-saving measures and their impact on approval times and safety standards be publicly documented?

Sources

Primary Source: Federal Council approves increase in federal contribution to Swissmedic – news.admin.ch, 28.05.2026

Verification Status: ✓ 28.05.2026

This text was created with the support of an AI model. Editorial responsibility: clarus.news | Fact-check: 28.05.2026